BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Is This Chinese Pharmaceutical Stock Worth the Risk? ↗

November 03, 2022

BeiGene's shares are down this year, but it has two potential blockbusters.

Via The Motley Fool

BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting

November 03, 2022

From BeiGene

Via Business Wire

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

November 02, 2022

From BeiGene

Via Business Wire

European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting ↗

October 14, 2022

Via Benzinga

Analyst Ratings for BeiGene ↗

October 13, 2022

Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter:

Via Benzinga

UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer ↗

September 20, 2022

Via Benzinga

BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

October 26, 2022

From BeiGene

Via Business Wire

Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal ↗

October 19, 2022

Via Benzinga

New Drugs Approvals Bring No Relief for Ailing Innovent Bio ↗

October 18, 2022

Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its...

Via Benzinga

Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million ↗

October 15, 2022

Deals, financings, trials and approvals on the China biotech/pharma market.

Via Talk Markets

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL

October 14, 2022

From BeiGene

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022 ↗

October 13, 2022

Upgrades

Via Benzinga

BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins ↗

October 12, 2022

A smaller biotech tested its experimental leukemia drug against J&J's approved med.

Via Investor's Business Daily

BeiGene's Brukinsa Shows Superior Progression-Free Survival Versus JNJ's Treatment ↗

October 12, 2022

Via Benzinga

BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial

October 12, 2022

From BeiGene

Via Business Wire

NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment

September 19, 2022

From BeiGene

Via Business Wire

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

September 19, 2022

From BeiGene

Via Business Wire

BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors ↗

September 12, 2022

Via Benzinga

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

September 10, 2022

From BeiGene

Via Business Wire

Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay ↗

September 09, 2022

Key Takeaways: The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the...

Via Benzinga

BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 07, 2022

From BeiGene

Via Business Wire

U.S.-China Audit Deal Won't Slow Hong Kong Dual Listing Train, Analysts Say ↗

September 02, 2022

Key Takeaways: Despite a landmark U.S.-China information-sharing agreement, some predict dual listings in New York and Hong Kong will remain the preferred choice for Chinese...

Via Benzinga

7 Chinese Stocks to Sell While You Still Can ↗

September 02, 2022

These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure

Via InvestorPlace

Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday ↗

August 30, 2022

Gainers

Via Benzinga

Catalent, Tellurian And Other Big Losers From Monday ↗

August 30, 2022

U.S. stocks closed lower with the Dow Jones dropping around 185 points on Monday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket ↗

August 25, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading.

Via Benzinga

Tesla, Autodesk And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

August 25, 2022

Snowflake Inc. (NYSE: SNOW) surged 17.4% to $187.18 in pre-market trading after the company reported better-than-expected Q2 sales results and issued product revenue guidance.

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 23, 2022

Via Benzinga

BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China

August 23, 2022

From BeiGene

Via Business Wire

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher ↗

August 17, 2022

These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.

Via InvestorPlace

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.